Identify factors that predict a patient's length of stay (LOS). A retrospective study was conducted to identify current practice patterns and to validate scoring systems that can predict duration of hospitalization.
RESULTS:
Univariate analysis showed a significant positive correlation between hospital stay and INR (p < 0.001), lactate (p = 0.027), presence of positive blood culture (p = 0.003), and time between admission and plastic surgery consult (p = 0.002); age (p = 0.082), COPD (p = 0.076), and CKD (p = 0.076) all approached significance as positive univariate predictors. Conversely, LOS was inversely correlated with BMI (p = 0.044), serum bicarbonate (p = 0.009), hematocrit (p = 0.008), calcium (p = 0.001), alkaline phosphatase (p = 0.044) and albumin (p = 0.001), while prealbumin (p = 0.063) approached significance as a negative predictor. Univariate analysis showed that FGSI, LRINEC, NLR, and CCI were not significantly correlated with LOS, while CUPI score was shown to be a significant predictor of longer hospital stays (p = 0.005, coefficient = 10.5).
CONCLUSION:
Although the contemporary management of Fournier's gangrene has reduced mortality, patients still experience prolonged hospitalization for wound care and reconstruction. Our study suggests that early emphasis on supportive care, nutrition, and involvement of reconstructive surgeons can decrease a patient's LOS. The CUPI scoring system was derived to predict LOS and will need to be further validated in future studies.
Outcomes of Flap Coverage of Infected and Exposed Cardiac Ventricular Assist Devices
Presenter: Nadeera Dawlagala, MD Co-Authors: Vahe Fahradyan, MD; Kihyun Cho, MD; Antonio Rampazzo, MD, PhD; Bahar Bassiri Gharb, MD, PhD; James E. Zins, MD, FACS Affiliation: Cleveland Clinic, Cleveland, OH INTRODUCTION: Ventricular assist devices (VAD) are implantable cardiac devices, providing ventricular support for patients awaiting heart transplant and for those ineligible for transplant but require permanent (destination) therapy. On average, a destination therapy patient will depend on a VAD for 4.4 years. 1 An infected VAD poses a challenge as device removal may not be an option, and the patient may be too unstable for device exchange. Flap coverage is a potential treatment for infected or exposed devices by enabling wound healing and delivery of immune cells with its rich vasculature. [2] [3] [4] We study the outcomes of flap coverage on infected and/or exposed ventricular assist devices.
METHODS:
A retrospective chart review of infected VAD patients treated with flap from 1960-2016 at our institution was conducted. Data studied included infection type, flap harvested, and number and type of adjunct surgical procedures. Survival outcomes with flap coverage were also reviewed.
RESULTS:
From a review of 351 VAD patients, 11 flaps were used in nine infected VAD patients. There were seven males, and two females with an average age of VAD implant, and age of flap done at 55 ± 9.21 years, and 56.7 ± 9.4 years. Seven were destination therapy patients, and two were awaiting transplant. The most common infection was MRSA (n=4), and sites included driveline (4), pump pocket (5), and sternal wound (6). Flaps used were omentum (n=5), rectus abdominis (n=4), anterolateral thigh (n=1) and pectoralis major (n=1). Complications included abdominal wall hematoma after rectus flap, and omental flap necrosis. Additional procedures included debridement, VAC therapy, and incision and drainage. 
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The average number of procedures to treat the infection was 3.7 ± 3.11. The average number of procedures before and after flap was 1.3 ± 0.86 (range 0-3), and 1.3 ± 2.34 (range 0-7). Seven of the nine patients expired, with a mean survival of 9.7 ± 5.3 months after flap, and 19.9 ± 13.7 months after initial VAD placement. Eight flap patients continued to suffer from a chronic VAD infection at time of death or last follow up, five of which expired from a septic cause. The two potential heart transplant recipients expired from sepsis prior to transplant.
CONCLUSION:
Despite flap coverage, sepsis remains the lead cause of mortality in infected VAD patients.
